Palavras-chave
Sarcoma
Tratamento
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar as estratégias terapêuticas para o manejo do sarcoma de Kaposi (SK) em pacientes com HIV, considerando manifestações clínicas, evolução das intervenções, importância da educação em saúde e abordagens multidisciplinares. Métodos: Revisão bibliográfica na base PubMed, utilizando os descritores “kaposi”, “sarcoma” e “treatment” com operador booleano “AND”. Incluíram-se ensaios clínicos e estudos clínicos randomizados publicados entre 2018 e 2024, nos idiomas inglês e português. Excluíram-se artigos que abordassem outras patologias não relacionadas ao tema central. A seleção ocorreu em etapas: definição do tema, estabelecimento de categorias, aplicação de critérios, verificação, análise e organização dos dados.
Resultados: Identificaram-se 8.048 artigos. Após filtro por período (2018-2024), restaram 1.412; pela tipologia de estudo, 38; pela disponibilidade de texto completo gratuito, 33. Após leitura dos resumos e eliminação de duplicatas ou artigos fora do escopo, selecionaram-se 20 artigos para análise. Considerações finais: O manejo do SK exige abordagem personalizada e multidisciplinar. A imunoterapia e as terapias combinadas mostram-se promissoras. A educação em saúde é essencial para adesão ao tratamento, e a profilaxia de infecções oportunistas deve ser integrada ao cuidado, melhorando qualidade de vida e desfechos clínicos.
Referências
GATAULT MC, et al. Overview of Kaposi's Sarcoma: A Focus on the Pathophysiology and Treatment Options. Current Oncology Reports, 2021; 23(6): 1-11.
DURHAM R, et al. The Role of HIV in the Development of Kaposi's Sarcoma. HIV Medicine, 2020; 21(4): 278-287.
MORAIS J, et al. Clinical Features of Kaposi's Sarcoma: A Comprehensive Review. Journal of Dermatological Treatment, 2019; 30(5): 472-478.
REID R, et al. Clinical Management of Kaposi's Sarcoma in HIV-Infected Patients: A Review. AIDS Research and Human Retroviruses, 2019; 35(10): 892-901.
MALIK M, et al. Advances in the Treatment of Kaposi's Sarcoma: From Chemotherapy to Immunotherapy. The Oncologist, 2020; 25(12): e2101-e2112.
MANOLOPOULOS P, et al. Opportunistic Infections in Patients with Kaposi's Sarcoma: Impact on Survival. Infectious Disease Reports, 2021; 13(1): 27-36.
MALEK F, et al. Immunotherapy in Kaposi's Sarcoma: Current Perspectives and Future Directions. Cancer Treatment Reviews, 2021; 97: 102202.
MILLER R, et al. Combined Therapies for the Treatment of Kaposi's Sarcoma: A Systematic Review. Cancer, 2021; 127(6): 1025-1038.
KARL J, et al. Multidisciplinary Care for Patients with Kaposi's Sarcoma: Importance and Outcomes. Journal of Multidisciplinary Healthcare, 2020; 13: 839-847.
TAVARES J, et al. Health Education in Kaposi's Sarcoma: The Importance of Patient Awareness. Patient Education and Counseling, 2019; 102(9): 1640-1646.
SGADARI C, et al. Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly. Cancer Res Commun. 2024; 4(8): 2112-2122.
ANIDI IU, et al. Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma. Open Forum Infect Dis., 2024; 11(5).
RAMON-LUING LA, et al. Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients. Clin Exp Immunol., 2024; 215(2): 190-201.
RUBINSTEIN PG, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol., 2023; 10(8).
HAIGENTZ M Jr, et al. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res., 2023; 29(24): 5038-5046.
LURAIN K, et al. Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration. AIDS, 2023; 37(11): 1693-1703.
DORVIL N, et al. Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti. PLoS Med., 2023; 20(6).
VOLKOW P, et al. Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial. PLoS One, 2023; 18(5).
SABOURIN KR, et al. Evaluation of a training intervention to improve cancer care in Zimbabwe: Strategies to Improve Kaposi Sarcoma Outcomes (SIKO), a prospective community-based stepped-wedge cluster randomized trial. J Int AIDS Soc., 2022; 25(8).
ZER A, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol., 2022; 33(7): 720-727.
JI Y, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood., 2022; 139(11): 1619-1630.
CHANG AY, et al. Compression Therapy for HIV-Associated Kaposi Sarcoma Leg Lymphedema: Results of the Kenyan Improvised Compression for Kaposi Sarcoma Randomized Controlled Trial. JCO Glob Oncol., 2022; 8.
RAMASWAMI R, et al. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res., 2022; 28(5): 840-850.
NYIRENDA M, et al. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr., 2020; 84(4): 422-429.
KROWN SE, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet, 2020; 395(10231): 1195-1207.
GRUFFAZ M, et al. Signatures of oral microbiome in HIV-infected individuals with oral Kaposi's sarcoma and cell-associated KSHV DNA. PLoS Pathog., 2020; 16(1).
REID EG, et al. Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. Clin Cancer Res., 2020; 26(3): 558-565.
KANG M, et al. Interim monitoring in a treatment strategy trial with a composite primary endpoint. Contemp Clin Trials, 2019; 86: 105846.
IRIRA M, et al. Prevalence and Outcome of HIV-associated Malignancies Among HIV-infected Children Enrolled into Care at Kilimanjaro Christian Medical Center 2006 to 2014: A Hospital-based Retrospective Analytical Study. J Pediatr Hematol Oncol., 2020; 42(1): 69-73.
SHAIK F, et al. Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial. J Glob Oncol., 2018; 4: 1-9.